Molecular Tumor Board Solutions Market Report 2025

The molecular tumor board solutions market size has grown rapidly in recent years. It will grow from $1.34 billion in 2024 to $1.53 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth during the historic period was driven by increasing adoption of genomic profiling, rising demand for precision oncology, growing awareness of molecular diagnostics, expansion of cancer research initiatives, and increasing collaborations between hospitals and biotech firms.

The molecular tumor board solutions market size is expected to see rapid growth in the next few years. It will grow to $2.53 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth during the forecast period is fueled by rising demand for multidisciplinary tumor boards, expansion of cloud-based molecular data platforms, increasing regulatory support for genomic testing, greater focus on patient-centric oncology care, and rising incidence of cancer cases. The primary trends in the forecast period include advancements in genomic sequencing tools, increased investment in research and development for molecular solutions, innovation in clinical decision support software, improvements in data analytics and visualization, and integration of machine learning for treatment recommendations.

The increasing prevalence of cancer is expected to drive the growth of the molecular tumor board solutions market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body. The rising incidence of cancer can be attributed to lifestyle factors such as poor diet, smoking, lack of physical activity, and excessive alcohol consumption. Molecular tumor board solutions support cancer care by offering expert, multidisciplinary reviews of patients’ genomic and clinical data, helping to develop personalized treatment plans. By integrating molecular profiling with AI-driven insights, these solutions enhance clinical decision-making, improving treatment precision and patient outcomes. For example, in October 2024, the National Health Service (NHS) reported a 5% increase in new cancer diagnoses, from 329,664 cases in 2021 to 346,217 in 2022, averaging 948 new cases per day. As a result, the rising cancer prevalence is contributing to the growth of the molecular tumor board solutions market.

Companies in the molecular tumor board solutions market are focusing on developing innovative molecular profiling tests to improve the accuracy and effectiveness of cancer diagnostics and treatment planning. Molecular profiling tests analyze a tumor’s genetic and molecular features to guide personalized treatment decisions. For example, in April 2025, Guardant Health Inc., a US-based biotechnology company specializing in precision oncology, launched Guardant360 Tissue, an advanced molecular profiling test for tumor tissue. This test incorporates comprehensive multiomic analysis, including DNA, RNA, AI-powered PD-L1, and genome-wide methylation data. Powered by the Guardant Infinity smart liquid biopsy platform, Guardant360 Tissue offers a more complete view of cancer, enabling more accurate tumor classification and subtyping. Results are delivered in less than two weeks, and the test is covered by Medicare for eligible patients. It aims to enhance precision oncology by providing valuable insights to guide treatment decisions, including therapies such as PARP inhibitors and immunotherapies.

In September 2024, Labcorp Holdings Inc., a US-based healthcare company, acquired BioReference Health LLC for $237.5 million. This acquisition enables Labcorp to expand its laboratory services network and broaden access to clinical testing for patients, physicians, and customers in key regions. BioReference Health LLC specializes in molecular tumor board solutions, offering comprehensive genomic testing and a wide range of diagnostic tests.

Major players in the molecular tumor board solutions market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Illumina Inc., Novogene Co. Ltd., QIAGEN N.V., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Mayo Clinic Laboratories, Sectra AB, GenomOncology LLC, MedGenome Labs Ltd., Burning Rock Biotech Limited, NantHealth Inc., SOPHiA GENETICS SA, Variantyx Inc., Baylor Genetics, Molecular Health GmbH, PierianDx Inc., Oncompass Medicine, and CureMatch Inc.

North America was the largest region in the molecular tumor board solutions market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in molecular tumor board solutions report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the molecular tumor board solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Molecular tumor board solutions are advanced platforms designed to support multidisciplinary clinical teams in analyzing cancer cases by integrating detailed patient-specific molecular and genomic information. These solutions enable the identification of actionable genetic mutations, evaluation of targeted therapy options, and discussion of relevant clinical trials, thereby facilitating informed and personalized treatment decisions.

The primary components of molecular tumor board solutions are software and services. Software includes digital platforms and applications that integrate patient data, analyze genetic profiles, and provide treatment recommendations for cancer care. These solutions can be deployed via on-premises or cloud-based systems and are applied in areas such as clinical decision support, genomic data interpretation, and patient management. Key end users include hospitals, cancer centers, research institutes, and other healthcare organizations.

The molecular tumor board solutions market research report is one of a series of new reports that provides molecular tumor board solutions market statistics, including molecular tumor board solutions industry global market size, regional shares, competitors with a molecular tumor board solutions market share, detailed molecular tumor board solutions market segments, market trends and opportunities, and any further data you may need to thrive in the molecular tumor board solutions industry. This molecular tumor board solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The molecular tumor board solutions market includes revenues earned by entities through providing expert clinical consultations, personalized treatment recommendations, and decision-support services to healthcare providers and patients. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.